Results 111 to 120 of about 101,002 (279)

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis [PDF]

, 2010
Background Nonalcoholic steatohepatitis is a common liver disease that can progress to cirrhosis. Currently, there is no established treatment for this disease.
Bass, Nathan M., Brunt, Elizabeth M., Chalasani, Naga, Clark, Jeanne, Diehl, Anna Mae, Hoofnagle, Jay H., Kleiner, David E., Kowdley, Kris V., Lavine, Joel E., McCollough, Arthur, Neuschwander-Tetri, Brent A., Robuck, Patricia R., Sanyal, Arun J., Tonascia, James, Unalp, Aynur, Van Natta, Mark   +15 more
core   +2 more sources

PD‐1/PD‐L1 in Hepatocellular Carcinoma (2014–2024): A Combined Macro and Micro Analysis of Immunotherapy Implications

iNew Medicine, EarlyView.
ABSTRACT Hepatocellular carcinoma (HCC) represents a significant global health issue, with the PD‐1/PD‐L1 axis serving a pivotal target for immunotherapy in this malignancy. However, a comprehensive bibliometric analysis of PD‐1/PD‐L1 research in HCC is lacking.
Xingyu Zhu, Lin Tang, Hongyan Li, Hao Li, Jiamei Wang   +4 more
wiley   +1 more source

Sex Differences in the Association Between Frailty and Sarcopenia in Patients With Cirrhosis. [PDF]

, 2019
ObjectivesFrailty is prevalent in patients with cirrhosis and is hypothesized to result in part from sarcopenia, but the precise contribution of sarcopenia to frailty in this population is poorly understood.MethodsIncluded were patients with cirrhosis ...
Bhanji, Carey, Dasarathy, DiMartini, Englesbe, Fried, Kuo, Lai, Lai, Lai, Lang, Montano-Loza, Montano-Loza, Riggio, Sinclair, Tandon, Wang, Yadav   +17 more
core   +2 more sources

Vibration‐controlled transient elastography in pediatric metabolic dysfunction‐associated steatotic liver disease

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a prevalent disease in children. Vibration‐controlled transient elastography (VCTE) offers a noninvasive alternative to liver biopsy, using controlled attenuation parameter (CAP) to estimate steatosis and liver stiffness measurement (LSM) for fibrosis.
Lauren B. Nichols, Sebastian G. J. Oakes, Cynthia Behling, Kathryn Harlow Adams, Mark H. Fishbein, Paula Hertel, Chao Jarasvaraparn, Jean P. Molleston, Marialena Mouzaki, Claude B. Sirlin, Miriam B. Vos, Laura A. Wilson, Stavra A. Xanthakos, Jeffrey B. Schwimmer, for the NASH CRN   +14 more
wiley   +1 more source

Potential Hepatic Lipid Markers Associated with Nonalcoholic Steatohepatitis and Fibrosis in Morbid Obesity Patients [PDF]

, 2023
Hua-Chien Wu, Yin-Ru Hsieh, Weu Wang, Ching-Wen Chang, I‐Wei Chang, Chi‐Long Chen, Chun‐Chao Chang, Chia‐Hsuan Chang, Wei‐Yu Kao, Shih‐Yi Huang   +9 more
openalex   +1 more source

Preliminary evidence of improved liver biomarkers in adolescents with obesity and suspected metabolic dysfunction‐associated steatotic liver disease treated with semaglutide: A case series

JPGN Reports, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects 30%–40% of youth with obesity and lacks approved pharmacologic therapies. In this single‐center retrospective case series at a tertiary care safety‐net children's hospital, we evaluated five adolescents (mean age: 17.0 years; 100% Hispanic; 60% male; mean body mass index:
Rachel Schenker, Katya Fomenko, Fotini T. Mitsinikos, Alaina P. Vidmar   +3 more
wiley   +1 more source

Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity

Hepatology Communications, 2018
Emerging data highlight the critical role for the innate immune system in the progression of nonalcoholic fatty liver disease (NAFLD). Connexin 32 (Cx32), the primary liver gap junction protein, is capable of modulating hepatic innate immune responses ...
Jay Luther, Manish K. Gala, Nynke Borren, Ricard Masia, Russell P. Goodman, Ida Hatoum Moeller, Erik DiGiacomo, Alyssa Ehrlich, Andrew Warren, Martin L. Yarmush, Ashwin Ananthakrishnan, Kathleen Corey, Lee M. Kaplan, Sangeeta Bhatia, Raymond T. Chung, Suraj J. Patel   +15 more
doaj   +1 more source

Recent update: Nonalcoholic steatohepatitis

Journal of Marine Medical Society, 2018
Nonalcoholic fatty liver disease has been traditionally conceptualized as a histological disease spectrum which progresses from simple steatosis or pure fatty liver through liver fibrosis or Nonalcoholic Steatohepatitis (NASH) to cirrhosis and eventually
Vivek Hande, Jnanaprakash B Karanth, P C Hande   +2 more
doaj   +1 more source

Activation of Adenosine Monophosphate—Activated Protein Kinase Reduces the Onset of Diet‐Induced Hepatocellular Carcinoma in Mice

Hepatology Communications, 2020
The worldwide obesity and type 2 diabetes epidemics have led to an increase in nonalcoholic fatty liver disease (NAFLD). NAFLD covers a spectrum of hepatic pathologies ranging from simple steatosis to nonalcoholic steatohepatitis, characterized by ...
Dieter Schmoll, Nicole Ziegler, Benoit Viollet, Marc Foretz, Patrick C. Even, Dalila Azzout‐Marniche, Andreas Nygaard Madsen, Martin Illemann, Karen Mandrup, Michael Feigh, Jörg Czech, Heiner Glombik, Jacob A. Olsen, Wolfgang Hennerici, Klaus Steinmeyer, Ralf Elvert, Tamara R. Castañeda, Aimo Kannt   +17 more
doaj   +1 more source

Vitamin D to reduce liver fibrosis in non-alcoholic fatty liver disease [PDF]

, 2017
BACKGROUND: As the prevalence of metabolic risk factors in the American population has increased over time, so too has the diagnoses of non-alcoholic fatty liver disease (NAFLD).
Fox, Ryan
core